trending Market Intelligence /marketintelligence/en/news-insights/trending/08eZ5QxFmPsNVV7RqaUe4w2 content esgSubNav
In This List

Fosun Pharma to commercialize Ardelyx's tenapanor in China

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Fosun Pharma to commercialize Ardelyx's tenapanor in China

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. secured exclusive rights to develop and commercialize Ardelyx Inc.'s drug tenapanor in China for an up-front payment of $12 million.

Ardelyx will also receive additional milestone payments up to $113 million and royalty payments on future net sales.

The drug will be commercialized for patients with irritable bowel syndrome with constipation and to treat hyperphosphatemia related to chronic kidney disease. Fosun Pharma will also commercialize the drug for other indications already approved in the U.S.

Tenapanor is an investigational oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx.